Novartis Zomaril

Schizophrenia drug iloperidone shows "at 16 mg level a significantly different efficacy level as compared to placebo," Novartis said during an Oct. 11 teleconference. "The Pink Sheet" (Oct. 16, p. 14) incorrectly reported that the comparator agent in the trial was J&J's Risperdal. Novartis licenses Zomaril from South San Francisco-based Titan Pharmaceuticals. "Novartis' timeline for NDA submission for Zomaril is fourth quarter 2001," Titan said